

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>5</sup> :</b> <b>C12P 21/08, A61K 39/395</b> <b>C12N 15/13, C07K 15/28</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 92/01059</b> <b>(43) International Publication Date:</b> <b>23 January 1992 (23.01.92)</b>
<b>(21) International Application Number:</b> <b>PCT/GB91/01108</b> <b>(22) International Filing Date:</b> <b>5 July 1991 (05.07.91)</b> <b>(30) Priority data:</b> <b>9014932.9 5 July 1990 (05.07.90) GB</b> <b>PCT/GB90/02017 21 December 1990 (21.12.90) WO</b> <b>(34) Countries for which the regional or international application was filed:</b> <b>GB et al.</b> <b>(71) Applicant (for all designated States except US):</b> <b>CELLTECH LIMITED [GB/GB]; 216 Bath Road, Slough, Berkshire SL1 4EN (GB).</b> <b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only) :</b> <b>ADAIR, John, Robert [GB/GB]; 23 George Road, Stokenchurch, High Wycombe, Buckinghamshire HP14 3RN (GB). BODMER, Mark, William [GB/GB]; Rose Cottage, 5 Manor Road, South Hinksey, Oxford OX1 5AS (GB). MOUNTAIN, Andrew [GB/GB]; 4 St. Michael's Cottages, Old Wokingham Road, Wokingham, Berkshire RG11 3DU (GB). OWENS, Raymond, John [GB/GB]; 23 Hamilton Avenue, Henley-on-Thames, Oxfordshire RG9 1SH (GB).</b>		<b>(74) Agent:</b> <b>MERCER, Christopher, Paul; Carpmaels &amp; Ransford, 43 Bloomsbury Square, London WC1A 2RA (GB).</b> <b>(81) Designated States:</b> <b>AT, AT (European patent), AU, BB, BE (European patent), BF (OAPI patent), BG, BJ (OAPI patent), BR, CA, CF (OAPI patent), CG (OAPI patent), CH, CH (European patent), CI (OAPI patent), CM (OAPI patent), CS, DE, DE (European patent), DK, DK (European patent), ES, ES (European patent), FI, FR (European patent), GA (OAPI patent), GB, GB (European patent), GN (OAPI patent), GR (European patent), HU, IT (European patent), JP, KP, KR, LK, LU, LU (European patent), MC, MG, ML (OAPI patent), MN, MR (OAPI patent), MW, NL, NL (European patent), NO, PL, RO, SD, SE, SE (European patent), SN + (OAPI patent), SU, TD (OAPI patent), TG (OAPI patent), US.</b> <b>Published</b> <b>With international search report.</b>
<b>(54) Title:</b> <b>CDR GRAFTED ANTI-CEA ANTIBODIES AND THEIR PRODUCTION</b> <b>(57) Abstract</b> <p>The present invention provides humanised antibody molecules (HAMs) having specificity for carcinoembryonic antigen (CEA) and having an antigen binding site wherein at least one of the complementarity determining regions (CDRs) of the variable domains is derived from the mouse monoclonal antibody A5B7 (A5B7 MAb) and the remaining immunoglobulin-derived parts of the HAM are derived from a human immunoglobulin. The HAMs may be chimeric humanised antibodies or CDR-grafted humanised antibodies and are preferably produced by recombinant DNA techniques. The HAMs are useful for <i>in vivo</i> diagnosis and therapy.</p>		

+ See back of page

AM7

**+ DESIGNATIONS OF "SU"**

It is under examination in which parts of the former Soviet Union the designation of the Soviet Union has effect.

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	ES	Spain	MG	Madagascar
AU	Australia	FI	Finland	ML	Mali
BB	Barbados	FR	France	MN	Mongolia
BE	Belgium	GA	Gabon	MR	Mauritania
BF	Burkina Faso	GB	United Kingdom	MW	Malawi
BG	Bulgaria	GN	Guinea	NL	Netherlands
BJ	Benin	GR	Greece	NO	Norway
BR	Brazil	HU	Hungary	PL	Poland
CA	Canada	IT	Italy	RO	Romania
CF	Central African Republic	JP	Japan	SD	Sudan
CG	Congo	KP	Democratic People's Republic of Korea	SE	Sweden
CH	Switzerland	KR	Republic of Korea	SN	Senegal
CI	Côte d'Ivoire	LI	Liechtenstein	SU	Soviet Union
CM	Cameroon	LK	Sri Lanka	TD	Chad
CS	Czechoslovakia	LU	Luxembourg	TG	Togo
DE	Germany	MC	Monaco	US	United States of America
DK	Denmark				

- 1 -

CDR grafted Anti-CEA antibodies and their production

#### FIELD OF THE INVENTION

The present invention relates to humanised antibody molecules (HAMS) having specificity for Carcinoembryonic Antigen (CEA) and to processes for their production using recombinant DNA technology.

The term "humanised antibody molecule" (HAM) is used to describe a molecule having an antigen binding site derived from an immunoglobulin from a non-human species, the remaining immunoglobulin-derived parts of the molecule being derived from a human immunoglobulin. The antigen binding site may comprise either complete variable regions fused onto human constant domains or only the complementarity determining regions (CDRs) grafted onto appropriate human framework regions in the variable domains. The abbreviation "MAb" is used to indicate a monoclonal antibody.

In the description, reference is made to publications by number, and these publications are listed in numerical order at the end of the description.

#### BACKGROUND OF THE INVENTION

Natural immunoglobulins have been known for many years, as have the various fragments thereof, such as the Fab, (Fab')<sub>2</sub> and Fc fragments, which can be derived by enzymatic cleavage. Natural immunoglobulins comprise a generally Y-shaped molecule having an antigen-binding site towards the outer end of each upper arm. The remainder of the structure, and particularly the stem of the Y, mediates the effector functions associated with immunoglobulins.

- 2 -

Natural immunoglobulins have been used in assay, diagnosis and, to a more limited extent, therapy. However, such uses, especially in therapy, have been hindered by the polyclonal nature of natural immunoglobulins. A significant step towards the realisation of the potential of immunoglobulins as therapeutic agents was the discovery of procedures for the production of monoclonal antibodies of defined specificity (1). However, most MAb's are produced by hybridomas which are fusions of rodent spleen cells with rodent myeloma cells. The resultant MAb's are therefore essentially rodent proteins. There are very few reports of the production of human MAb's.

Since most available MAb's are of rodent origin, they are naturally antigenic in humans and thus can give rise to an undesirable immune response termed the HAMA (Human Anti-Mouse Antibody) response. Therefore, the use of rodent MAb's as therapeutic agents in humans is inherently limited by the fact that the human subject will mount an immunological response to the MAb and will either remove it entirely or at least reduce its effectiveness.

Therefore proposals have been made for making non-human MAb's less antigenic in humans. Such techniques can be generically termed "humanisation" techniques. These techniques generally involve the use of recombinant DNA technology to manipulate DNA sequences encoding the polypeptide chains of the antibody molecule.

Early methods for humanising MAb's related to production of chimeric antibodies in which an antigen binding site comprising the complete variable domains of one antibody are fused to constant domains derived from a second antibody. Methods for carrying out such chimerisation procedures are described in EP0120694 (Celltech Limited);

- 3 -

EP0125023 (Gen ntech Inc.), EP-A-0171496 (Res. Dev. Corp. Japan), EP-A-0173494 (Stanford University), and EP-A-0194276 (Celltech Limited). The Celltech EP 0194276 application discloses a process for preparing an antibody molecule having the variable domains from a mouse MAb and the constant domains from a human immunoglobulin. It also describes the production of an antibody molecule comprising the variable domains of a mouse MAb, the CH1 and CL domains of a human immunoglobulin, and a non-immunoglobulin-derived protein in place of the Fc portion of the human immunoglobulin.

Subsequently a number of further patent applications have been published relating to chimeric antibodies, including tumour specific chimeric antibodies (e.g. WO 87/02671, Int. Gen. Eng. Inc.; EP 0256654, Centocor; EP 0266663, Int. Gen. Eng. Inc. & Oncogen; WO 89/00999, Int. Gen. Eng. Inc. and EP 0332424, Hybritech Inc.). The Genentech (EP0125023) and Hybritech (EP0332424) patent application relate to anti-carcinoembryonic antigen (anti-CEA) chimeric antibodies.

Such humanised chimeric antibodies, however, still contain a significant proportion of non-human amino acid sequence, i.e. the complete variable region domains. Thus such humanised antibodies may elicit some HAMA response, particularly if administered over a prolonged period [Begent et al (ref. 2)].

In an alternative approach, described in EP-A-02394000 (Winter), the complementarity determining regions (CDRs) of a mouse MAb have been grafted onto the framework regions of the variable domains of a human immunoglobulin by site directed mutagenesis using long oligonucleotides. Such CDR-grafted humanised antibodies are less likely to

- 4 -

give rise to a HAMA response than humanised chimeric antibodies in view of the lower proportion of non-human amino acid sequence which they contain. There are 3 CDRs (CDR1, CDR2 and CDR3) in each of the heavy and light chain variable regions.

The earliest work on CDR-grafted humanised MAb was carried out on MAb recognising synthetic antigens, such as the NP or NIP antigens. However, recently examples in which a mouse MAb recognising lysozyme and a rat MAb recognising an antigen on human T cells respectively were humanised have been described by Verhoeven et al (3) and Riechmann et al (4). The preparation of the CDR-grafted antibody to the antigen on human T cells is also described in WO 89/07452 (Medical Research Council). More recently Queen et al (5) have described the preparation of a humanised CDR-grafted antibody that binds to the interleukin 2 receptor.

It has been widely suggested that immunoglobulins, and in particular MAb, could potentially be very useful in the diagnosis and treatment of cancer (6, 7). There has therefore been much activity in trying to produce immunoglobulins or MAb directed against tumour-specific antigens. So far, over one hundred MAb directed against a variety of human carcinomas have been used in various aspects of tumour diagnosis or treatment (8).

There have been a number of papers published concerning the production of chimeric monoclonal antibodies recognising cell surface antigens. For instance, Sahagan et al (9) disclose a genetically engineered murine/human chimeric antibody which retains specificity for a tumour-associated antigen. Also Nishimura et al (10) disclose a

- 5 -

recombinant murine/human chimeric monoclonal antibody specific for common acute lymphocytic leukemia antigen.

We have now prepared humanised antibodies to carcinoembryonic antigen derived from the anti-CEA mouse MAb A5B7 (11).

Our copending International Patent Application PCT/GB 90/02017 relates to the CDR-grafting of antibodies in general and describes, among other things, that antibodies having specificity for cancer markers such as CEA, e.g. the A5B7 monoclonal antibody, have been successfully CDR-grafted according to the procedure described therein.

#### SUMMARY OF THE INVENTION

According to the present invention, there is provided a humanised antibody molecule (HAM) having specificity for carcinoembryonic antigen (CEA) and having an antigen binding site wherein at least one of the complementarity determining regions (CDRs) of the variable domain is derived from the mouse monoclonal antibody A5B7 (A5B7 MAb) and the remaining immunoglobulin-derived parts of the HAM are derived from a human immunoglobulin.

#### GENERAL DESCRIPTION OF THE INVENTION

The HAM may comprise a chimeric humanised antibody or a CDR-grafted humanised antibody. When the HAM comprises a CDR-grafted humanised antibody, the heavy and/or light chain variable domains may comprise only one or two A5B7 derived CDRs; though preferably all three heavy and light chain CDRs are derived from A5B7.

The A5B7 MAb is a mouse MAb of the type IgG1-Kappa raised against purified CEA which had been denatured by heating to 85°C for 35 minutes. The A5B7 MAb has been

- 6 -

extensively studied at Charing Cross Hospital, London, UK (11). Immunohistochemical studies have demonstrated that the A5B7 MAb reacts with CEA producing tumours. Its distribution is within malignant glands in the cell cytoplasm, at the cell surface and in necrotic debris. However, it shows no significant cross-reactivity with a wide spectrum of normal human tissues. The molecular cloning and sequencing of the A5B7 heavy and light chain cDNAs is described hereinafter and the  $V_L$  and  $V_H$  cDNA and predicted amino acid sequences are given in Figure 1.

Surprisingly it has been found that humanising the A5B7 MAb, in particular by CDR-grafting, does not substantially adversely affect its binding activity, and this produces a HAM which is extremely useful in both therapy and diagnosis of certain carcinomas.

Preferably, the HAM of the present invention is produced by recombinant DNA technology.

The HAM of the present invention may comprise: a complete antibody molecule, having full length heavy and light chains; a fragment thereof, such as the Fab, Fab', (Fab')<sub>2</sub> or FV fragment; a single chain antibody fragment, e.g. a single chain FV; a light chain or heavy chain monomer or dimer; including fragments or analogues of any of these or any other molecule with the same specificity as the A5B7 antibody.

The HAM of the present invention may have attached to it an effector or reporter molecule. For instance, the HAM may have a macrocycle for chelating a heavy metal atom, or a toxin such as ricin, attached to it by a covalent bridging structure. Alternatively, the procedures of recombinant DNA technology may be used to produce a HAM in



- 7 -

which the Fc fragment, CH3 or CH4 domain of a complete antibody molecule has been replaced by or has attached thereto by peptide linkage a functional non-immunoglobulin protein, such as an enzyme or toxin molecule.

The remaining non-A5B7, immunoglobulin derived parts of the HAM may be derived from any suitable human immunoglobulin. For instance, when the HAM is a CDR-grafted HAM, appropriate variable region framework sequences may be used having regard to class/type of the A5B7 donor antibody from which the antigen binding regions are derived. Preferably, the type of human framework used is of the same/similar class/type as the donor antibody (A5B7 is IgG1 Kappa). Advantageously, the framework is chosen to maximise/optimize homology with the donor antibody sequence particularly at positions spacially close or adjacent to the CDRs. Examples of human frameworks which may be used to construct CDR-grafted HAMs are LAY, POM, TUR, TEI, KOL, NEWM, REI and EU; for instance KOL and NEWM for the heavy chain and REI for the light chain and EU for both the heavy chain and the light chain. Preferably the LAY framework is used as the human framework for both heavy and light chain variable domains, in view of its high level of homology with A5B7.

Also human constant region domains of the HAM may be selected having regard to the proposed function of the antibody, in particular the effector functions which may be required. For example, the constant region domains may be human IgA, IgE, IgG or IgM domains. In particular, IgG human constant region domains may be used especially of the IgG1 and IgG3 isotypes, when the HAM is intended for therapeutic purposes and antibody effector functions are required. Alternatively, IgG2 and IgG4 isotypes may

be used when the HAM is intended for purposes for which antibody effector functions are not required e.g. for imaging, diagnostic or cytotoxic targeting purposes.

However, the remainder of the HAM need not comprise only protein sequences from human immunoglobulins. For instance, a gene may be constructed in which a DNA sequence encoding part of a human immunoglobulin chain is fused to a DNA sequence encoding the amino acid sequence of a polypeptide effector or reporter molecule.

According to a second aspect of the present invention, there is provided a process for producing the HAM of the first aspect of the invention, which process comprises:

- (a) producing in an expression vector an operon having a DNA sequence which encodes an antibody heavy or light chain comprising a variable domain wherein at least one of the CDRs of the variable domain is derived from the A5B7 MAb and the remaining immunoglobulin-derived parts of the antibody chain are derived from a human immunoglobulin;
- (b) producing in an expression vector an operon having a DNA sequence which encodes a complementary antibody light or heavy chain comprising a variable domain wherein at least one of the CDRs of the variable domain is derived from the A5B7 MAb and the remaining immunoglobulin-derived parts of the antibody chain are derived from a human immunoglobulin;
- (c) transfecting a host cell with the or each vector;

and

- 9 -

- (d) culturing the transfected cell line to produce the HAM.

The cell line may be transfected with two vectors, the first vector containing an operon encoding a light chain-derived polypeptide and the second vector containing an operon encoding a heavy chain-derived polypeptide. Preferably, the vectors are identical except in so far as the coding sequences and selectable markers are concerned so as to ensure as far as possible that each polypeptide chain is equally expressed.

Alternatively, a single vector may be used, the vector including the sequences encoding both light chain- and heavy chain-derived polypeptides.

Thus in further aspects the invention also includes DNA sequences coding for the heavy and light chains, cloning and expression vectors containing the DNA sequences, host cells transformed with the DNA sequences and processes for producing the heavy and/or light chains and antibody molecules comprising expressing the DNA sequences in the transformed host cells.

The general methods by which the vectors may be constructed, transfection methods and culture methods are well known per se. Such methods are shown, for instance, in references 12 and 13.

The DNA sequences which encode the A5B7 amino acid sequence may be obtained by methods well known in the art. For example, the A5B7 coding sequences may be obtained by genomic cloning, or cDNA cloning from the A5B7 hybridoma cell line. Positive clones may be screened

- 10 -

using appropriate probes for the heavy and light chain genes in question. Also PCR cloning may be used.

DNA coding for human immunoglobulin sequences may be obtained in any appropriate way. For example, DNA sequences coding for preferred human acceptor frameworks such as LAY, POM, KOL, REI, EU, TUR, TEI and NEWM, are widely available to workers in the art.

The standard techniques of molecular biology may be used to prepare DNA sequences coding for the CDR-grafted products. Desired DNA sequences may be synthesised completely or in part using oligonucleotide synthesis techniques. Site-directed mutagenesis and polymerase chain reaction (PCR) techniques may be used as appropriate. For example, oligonucleotide directed synthesis as described by Jones et al (14) may be used. Also oligonucleotide directed mutagenesis of a pre-existing variable region as, for example, described by Verhoeven et al (3) or Riechmann et al (4) may be used. Also enzymatic filling in of gapped oligonucleotides using T<sub>4</sub> DNA polymerase as, for example, described by Queen et al (5) may be used.

Any suitable host cell/vector system may be used for expression of the DNA sequences coding for the chimeric CDR-grafted heavy and light chains. Bacterial e.g. E. coli, and other microbial systems may be used, in particular for expression of antibody fragments, e.g. FV, Fab and Fab' fragments, and single chain antibody fragments e.g. single chain FVs. Eucaryotic e.g. mammalian host cell expression systems may be used for production of larger CDR-grafted antibody products, including complete antibody molecules. Suitable

- 11 -

mammalian host cells include CHO cells and myeloma or hybridoma cell lines.

The present invention also includes therapeutic and diagnostic compositions containing the HAM of the invention and uses of such compositions in therapy and diagnosis.

Such therapeutic and diagnostic compositions typically comprise a HAM according to the invention in combination with a pharmaceutically acceptable excipient diluent or carrier, e.g. for in vivo use. Therapeutic and diagnostic uses typically comprise administering an effective amount of a HAM according to the invention to a human subject.

In the HAM of the first aspect of the invention and the process of the second aspect of the invention the heavy and light chain variable domains of the HAM may comprise either the entire variable domains of the A5B7 MAb or may comprise framework regions of a human variable domain having grafted thereon one, some or all of the CDRs of the A5B7 MAb. Thus the HAM may comprise a chimeric humanised antibody or a CDR-grafted humanised antibody.

When the HAM is a CDR-grafted humanised antibody, in addition to the CDRs, specific variable region framework residues may correspond to non-human, i.e. the A5B7 mouse, residues. Preferably the CDR-grafted humanised antibodies of the present invention include CDR-grafted humanised antibodies as defined in our co-pending patent application, International Patent Application PCT/GB 90/02017. The disclosure of PCT/GB 90/02017 is incorporated herein by reference.

- 12 -

Preferably the CDRs of the light chain correspond to the Kabat CDRs at CDR1 (positions 24-34) and CDR2 (positions 50-56) and to the structural loop residues (positions 91-96) or Kabat CDR residues (positions 89-97) in CDR3. In addition the light chain may have mouse residues at one or more of positions 1, 2 and/or 3, 46, 47, 49, 60, 70, 84, 85 and 87 and preferably has mouse residues at at least positions 46 and 47.

In addition to the CDRs, the HAM heavy chain preferably has mouse residues at positions 23 and/or 24 and 71 and/or 73. Additionally, the heavy chain may have mouse residues at one, some or all of positions 48 and/or 49, 69, 76 and/or 78, 80, 88 and/or 91 and 6. Preferably also, the CDRs of the heavy chain correspond to the Kabat CDR at CDR2 (positions 50-65), the structural loop residues at CDR3 (positions 95-100) and a composite of both the Kabat and structural loop residues at CDR1 (positions 24-35); for example, when the human variable region framework used is KOL. Alternatively, the CDRs of the heavy chain may comprise mouse residues at positions 26 to 35 for CDR1, positions 50 to 65 for CDR2 and positions 94 to 100 for CDR3; for example, when the human variable region framework used is EU. In addition EU has a particularly idiosyncratic J region between residues 103 to 113 and it may be useful to include the murine amino acids, or a consensus human J region or a suitable combination of both at residues 103 to 108 inclusive.

In a particularly preferred embodiment LAY human variable region frameworks are used for both the CDR-grafted heavy and light chains. In which case the light chain preferably comprises mouse A5B7 residues at positions 1, 2, 3, 4, 46 and 71, and especially also at positions 21, 47 and 73, of the variable region frameworks. Similarly,

- 13 -

the heavy chain preferably comprises mouse A5B7 residues at positions 1, 24, 48, 49, 72, 73, 76 and 93, and especially also at positions 82b and 86, of the variable region frameworks. Also when the LAY human variable region frameworks are used, the variable regions preferably comprises A5B7 mouse CDRs at residues 24 to 34 (CDR1) 50 to 56 (CDR2) and 89 to 97 (CDR3) for the light chain and at residues 26 to 35 (CDR1), 50 to 65 (CDR3) and 95 to 102 (CDR3) for the heavy chain.

The residue designations given above and elsewhere in the present application are numbered according to the Kabat numbering (15).

#### BRIEF DESCRIPTION OF THE DRAWINGS

The present invention is now described, by way of illustration only, in the following examples which refer to the accompanying diagrams Figures 1 - 16, in which:-

- Figure 1 shows the DNA sequences encoding the unprocessed variable regions of the A5B7 MAb obtained by sequencing cDNA clones together with the predicted amino acid sequence;
- Figure 2 is a schematic diagram of the construction by restriction and ligation of the chimeric heavy chain gene;
- Figure 3 is a schematic diagram of the construction by site-directed mutagenesis, restriction and ligation of the chimeric light chain gene;
- Figure 4 shows an ELISA analysis of COS-cell transfectant supernatants. The level of antigen-binding capacity in the supernatant of

- 14 -

COS-cell transfectants was analysed as described later. Dilution curves were plotted out against the optical density of the colour change;

- Figure 5 shows plasmid diagrams for plasmids pBG7, pBG11, pBG14, pHMC19, pHMC20 and pHMC21;
- Figure 6 shows plasmid diagrams for plasmids pHMC29, pHMC30 and pHMC31;
- Figure 7 shows a SDS-PAGE gel of chimeric FAb' and chimeric DFM products under both reducing and non-reducing conditions;
- Figure 8 shows the DNA and protein sequences for the A5B7 grafted light chain, gL-1 variable region;
- Figure 9 shows similar sequences for the A5B7 grafted light chain gL-2, variable region;
- Figure 10 shows similar sequences for the A5B7 grafted heavy chain gH1, variable region;
- Figure 11 shows similar sequences for the A5B7 grafted heavy chain gH2, variable region.
- Figure 12 shows plasmid diagrams for plasmids pMRR010, pMRR014, pAL43, pAL44, pAL45 and pAL46;
- Figure 13 is graphs showing the results of direct CEA binding ELISAs on supernatants from transient expression of chimeric/grafted hybrids and a chimeric/chimeric standard;



- 15 -

Figure 14 shows similar graphs for grafted/grafted transfections as well as the chimeric/chimeric standard;

Figure 15 shows plasmid diagrams of plasmids pMRR020, pAL45, pAL46, pAL49 and pAL50 indicating the derivation of the latter two plasmids;

Figure 16 shows plasmid diagrams of various plasmids indicating the derivation of plasmids pHMC43, pHMC44, pAL53 and pAL54;

Figure 17 shows plasmid diagrams for pACTac, pMMR28 and pMRR45;

Figure 18 shows graphs of CEA binding ELISAs on E. coli supernatants containing A5B7 chimeric Fab', and

Figure 19 shows similar graphs for A5B7 grafted Fab'.

DETAILED DESCRIPTION OF SPECIFIC  
EMBODIMENTS OF THE INVENTION

Example I

Molecular cloning and sequencing of the A5B7 heavy and light chain cDNAs

Polyadenylated RNA was isolated from the A5B7 hybridoma cell line using the guanidinium isothiocyanate/lithium chloride method (12). Double stranded cDNA was synthesised (16) and a cDNA library was constructed in plasmid pSP64 (17) vector using EcoRI linkers. Two screening probes were synthesised, complementary to mouse immunoglobulin heavy and light chain constant regions. The heavy chain probe was a 19 mer complementary to residues 115-133 in the CH1 domain of the mouse  $\gamma$  1 sequence (18). The light chain probe was a 20 mer complementary to residues 4658-4677 of the genomic mouse CK sequence (19). The probes were radio-labelled at the 5' terminus with [ $\gamma$   $^{32}$ P] ATP using T4 polynucleotide kinase (Amersham International) and used to screen the cDNA library.

Clones which contained the complete leader, variable and constant regions of both the heavy and light chains were isolated and designated as pBG1 and pBG2. Nucleotide sequence analysis was carried out according to the chain termination procedure (20).

The 950 base pair EcoRI insert in pBG1 was fully sequenced. The EcoRI insert in pBG2 was shown to comprise approximately 1700 base pairs by agarose gel electrophoresis. The variable domain and the 5' region of the CH1 domain were sequenced, as was the 3' end of the clone to confirm the presence of the correct mouse  $\gamma$  1

- 17 -

termination sequences. The DNA and predicted amino acid sequences for the unprocessed variable regions of pBG1 and pBG2 are shown in Figure 1.

With reference to Figure 1. Panel A shows the sequence coding for the  $V_L$  region and the predicted amino acid sequence. Panel B shows the sequence coding for the  $V_H$  region together with the predicted amino acid sequence. The putative sites of cleavage of the signal peptide are indicated by arrows. Examination of the derived amino acid sequence revealed considerable homology with other characterised immunoglobulin genes, and enabled the extent of the leader, variable and constant domains to be accurately determined. In addition MAb A5B7 was confirmed to be an IgG1 K antibody.

Example 2Preparation and Testing of Chimeric Antibody ProductsA. Construction of Chimeric Mouse-Human Heavy Chain Genes

The construction of vectors containing the human constant region isotype series, pRB18(IgG1), pRB26(IgG2), pRB20(IgG3) and pRB21(IgG4) is described in published International Patent Application WO 89/01783. The A5B7 V<sub>H</sub> DNA sequence was isolated as a EcoRI-BanI fragment and was ligated to the following linking oligonucleotide to give an EcoRI-HindIII V<sub>H</sub> fragment (Figure 2).

R1120 5' GCACCACTCTCACCGTGAGCTC

R1121 GTGAGAGTGGCACTCGAGTCGA5'

This fragment was ligated to the human HindIII-BamHI containing fragments of the IgG1, 2, 3 & 4 genes cloned in pAT153 to give pBG3, 4, 5 & 6.

The chimeric heavy chain genes were isolated as EcoRI-BamHI fragments from the pAT IgG plasmids and cloned into pEE6 vector (21) cut with EcoRI & BclI, to give plasmids pBG 7,8,9 & 10. The pEE6 plasmid contains the strong promoter/enhancer and transcriptional control element from the human cytomegalovirus immediate early gene (hCMV-IE) inserted into a unique HindIII site upstream of the EcoRI site and is described in detail in published International Patent Application WO 89/01036. In addition, an SV40 origin of replication is provided by the SV40 early promoter fragment which drives as selectable marker gene, a guanine phosphoribosyl transferase gene (gpt) inserted into a unique BamHI site. The plasmid also contains an ampicillin-resistance gene allowing selection and propagation in bacterial hosts.

- 19 -

B. Construction of the Chim ric Mouse-Human Light Chain Gene

A HindIII restriction enzyme site was introduced into the mouse light chain cDNA clone, pBG1 by site-directed mutagenesis (23) using the following oligonucleotide:-

5' TTTGATTTCAAGCTTGGTGC 3'

Introduction of the HindIII site was verified by DNA sequencing. The A5B7 V<sub>L</sub> sequence was isolated as an EcoRI/HindIII fragment. It was combined with a HindIII/EcoRI fragment comprising the human Ck constant region and ligated into the unique EcoRI site of pEE6. (Figure 3). The resulting plasmid pHMC19 also contained the neomycin-resistant gene (neo) under the control of the SV40 early promoter.

C. Transfections and ELISA Analysis of Antibody Production

The four chimeric heavy chain expression constructs described above were transfected together with chimeric light chain into COS-1 cells (24) for transient expression of chimeric products. The cells were left to incubate in DNA-DEAE dextran solution for six hours, then shocked for two minutes with 10% DMSO in HEPES-buffered saline. The cells were washed and incubated in medium containing 10% foetal calf serum for 72 hours.

Following incubation at 37°C for 72 hours the cell supernatants were analysed by ELISA for heavy and light chain production and binding of antigen.

The medium (500 µl per 10<sup>6</sup> cells) was removed for ELISA analysis.

- 20 -

To quantify assembled antibody production Microtitre plates were coated with 0.25  $\mu$ g per well of sheep antibody reactive against human specific epitopes on the heavy or light chains. Supernatants or lysates from transfected COS cells were diluted 1:2 or 1:4 respectively in sample conjugate buffer containing 0.1M Tris-HCl pH 7.0, 0.1M sodium chloride, 0.02% Tween 20 and 0.2% casein. 100  $\mu$ l of each diluted sample were added to each well and incubated for 1 hour at room temperature with gentle agitation. Following washing six times with wash buffer (phosphate buffered saline containing 0.2% Tween 20, pH 7.2), 100  $\mu$ l of 1:5000 dilution of standard horseradish peroxidase - conjugated antibody reactive against human specific epitopes were added per well. The plates were incubated for 1 hour at room temperature, and then washed six times with wash buffer. 100  $\mu$ l of substrate buffer containing 0.1 mg/ml tetramethylbenzidine (TMB), 0.1M sodium citrate, pH 6.0 and 0.005% H<sub>2</sub>O<sub>2</sub> were added to each well to generate a colour change. The reaction was terminated after 2-3 minutes by adjusting the solution to pH 1.0 with 1.5M sulphuric acid. The optical density was determined at 450nm for each well by measurement in a Dynatech laboratories MR600 microplate reader. Standard curves were generated using known concentrations of the appropriate human immunoglobulins.

Antigen binding assays were performed in an analogous manner. Microtitre plates were coated with 0.25  $\mu$ g per well of purified CEA. Following washing six times in wash buffer, samples from COS-cell transfections were added as previously, and the same subsequent procedures carried out, using goat anti-mouse or -human F(ab')<sub>2</sub> linked to HRP as the second antibody.

- 21 -

Assembly assays, which detect the presence of associated polypeptide chains, demonstrated the formation of multimers containing at least one heavy and one light chain when both genes were co-transfected. Antigen binding analysis (see above) demonstrated that the chimeric heavy and chimeric light chain co-transfections generated an antibody molecule capable of recognising antigen. The antigen binding ELISA data from one experiment are presented in Figure 4. These experiments demonstrate that chimerisation of the antibody molecule does not have a significant effect on its antigen recognition capability.

D. Immunoprecipitation of Antibody Molecules from Biosynthetically Labelled COS-Cell Transfectants

Following transfection, COS cells were allowed to recover for 24 hours in DMEM containing 10% foetal calf serum. The medium was then replaced with methionine-free DMEM, to which [ $^{35}\text{S}$ ] methionine (NEN) had been added at 100  $\mu\text{Ci/ml}$ . The cells were metabolically labelled for 48 hours. Analysis of the assembly and secretion of antibody molecules was performed by immunoprecipitation using anti-human  $\text{F(ab')}_2$  bound to Protein A-Sepharose. Affinity-purified rabbit antibodies against human IgG  $\text{F(ab')}_2$  were used for immunoprecipitations, following coupling to Protein A - Sepharose. Secreted antibodies were analysed on a SDS-10% PAGE system under reducing and non-reducing conditions. The gel was treated with an autoradiography enhancer, dried and exposed to Fuji RX film.

The antiserum immunoprecipitated proteins with an apparent molecular weight of 55K and 28K, corresponding to the heavy and light immunoglobulin chains respectively. A comparison of immunoprecipitations analysed by reducing

- 22 -

and non-reducing SDS-PAGE indicated that the heavy and light chains were assembled as the correct tetrameric molecule.



- 23 -

Example 3Preparation and Comparison of Chimeric Whole Antibody and Fab' Products

Stable cell lines expressing chimeric whole antibody and Fab' products were established and chimeric whole antibody, Fab', F(ab')<sub>2</sub>, and synthetically cross-linked DFM (Di Fab' Maleimide) products were prepared and tested.

First of all, however, it was necessary to construct a DNA sequence coding for the chimeric Fab' and vectors for expression of this sequence.

A. Construction of Chimeric Mouse/Human Heavy Chain Gene and Vectors for Fab' Expression

The plasmid containing the A5B7 chimeric heavy chain, IgG4, (pBG10) was restricted with BstE11 and Bgl11. The larger vector fragment containing the hCMV promoter and A5B7 V<sub>H</sub> plus the 5' part of CH1 domain was isolated. The plasmid pJA115 (described in International Patent Application WO 89/01974) was restricted with BstE11 and Bgl11. A fragment containing the 3' end of CH1 plus the IgG4 hinge containing a cys to ala change was isolated and ligated into the pBG10 vector.

The resulting vector, pBG14, contains the A5B7 Fd' heavy chain IgG4 (cys to ala).

The Assay procedures used in this and subsequent Examples were as follows:

Assembly ELISAs

The ELISA for measuring yields of whole antibodies used microwell plates coated with goat F(ab')<sub>2</sub> IgG Fc. Humanised IgG bound following incubation with culture

- 24 -

supernatant samples was revealed with horseradish peroxidase (HRP) conjugated murine anti-human kappa chain antibody. Concentrations of chimeric or CDR-grafted whole antibody in samples were interpolated from a calibration curve generated from serial dilutions of purified chimeric A5B7 IgG1.

The ELISA for measuring yields of Fab's used microwell plates coated with murine anti-human IgG Fd. Following incubation with samples bound humanised Fab' was revealed as in the whole antibody assembly ELISA. Concentrations of chimeric or CDR-grafted A5B7 Fab' in samples were interpolated from a calibration curve generated from serial dilutions of purified chimeric A5B7 Fab'.

#### CEA Binding Assays

The direct CEA binding ELISA used microwell plates coated with CEA. Following incubation with serial dilutions of culture supernatant samples bound IgG or fragments was revealed as for the assembly ELISA. Binding versus dilution curves were normalised against antibody concentration as determined by the assembly assays.

The competition RIA for anti-CEA activity involved competition of a series of  $^{125}\text{I}$ -labelled murine or chimeric A5B7 IgG1 with humanised IgG or fragments thereof from culture supernatant samples for binding to CEA coated beads. Binding activity was determined by measuring bead associated radioactivity. The assay was calibrated by competition with standard preparations of chimeric or murine A5B7 IgG1 and plotting % bound cpm versus antibody concentration. Interpolated apparent A5B7 concentration of unknowns was normalised by dividing by the assembly assay result to give a specific activity. Finally specific activity was expressed as % relative potency by

- 25 -

comparison to that obtained from a positive control chimeric A5B7 culture supernatant produced during the same experiment.

The relative potency of purified murine and chimeric A5B7 Fab' and F(ab')<sub>2</sub> fragments and murine IgG was investigated using the competition RIA. In addition, the direct binding ELISA was run in competition mode, by coincubation of the test specimen with murine A5B7 IgG1, for confirmation of relative potency.

Chimeric A5B7 Fab' was purified by ion-exchange chromatography on DEAE-sepharose followed by hydrophobic interaction chromatography on octyl-sepharose. Cross-linking was carried out by the standard one pot procedure using 1,6-bismaleimido-hexane as cross-linker, with a 2.2 fold excess of Fab' to cross-linker at 0.9mg/ml. Due to the small scale of the experiment purification was carried out by HPLC gel filtration (GF-250XL). This yielded an A5B7 chimeric DFM (Di Fab' maleimide) product.

#### B. Development of CHO Cell Lines expressing Chimeric A5B7 IgG1 and Chimeric IgG4 Fab' delta cys

Two types of CHO cell line, amplifiable and non-amplifiable, were developed expressing chimeric A5B7 IgG1 whole antibody and chimeric A5B7 IgG4 Fab' delta cys. The chimeric A5B7 IgG1 whole antibody was used as a standard for assay development and for comparison of chimeric and grafted in biodistribution and therapy studies in tumour-bearing mice.

#### Non-amplifiable cell lines

Non-amplifiable cell lines for chimeric whole antibody and Fab' were first constructed. Although such cell lines

- 26 -

are relatively low yielding, they are more readily and rapidly prepared and were used for rapid generation of material for development of procedures for purification and for assays. pHMC19 (see Example 2) is a plasmid containing the chimeric A5B7 light chain 3' to the hCMV promoter. This plasmid was transfected into CHO-K1 cells with selection for neomycin resistance and spot assays performed on 30 transfectants with anti-human kappa antibody to identify the best producing clones. Assays with the same antibody on representative cell lines identified a stable cell line, designated HCN1.37, secreting the chimeric A5B7 light chain with a specific production rate of 1-2  $\mu\text{g}/\text{ml}/10^6$  cells. The cell line was retransfected with plasmids pBG7 and pBG14, as described previously, these plasmids carrying the heavy chain genes for chimeric A5B7 IgG1 and chimeric IgG4 Fab' delta cys respectively, in the pEE6hCMV gpt vector (see Figure 5). Cell lines yielding approximately 16mg/l chimeric IgG1 (designated HCN1.37/g1.1 and g1.7) and approximately 5mg/l chimeric Fab' (designated HCN1.37/delta cys3) after purification were identified among these retransfectants by assembly and direct CEA binding assays. These cell lines were used to make test quantities of chimeric whole antibody and Fab'.

#### Amplifiable Cell Lines

Cell lines capable of amplification by the GS vector system and intended to give yields of chimeric A5B7 Fab' delta cys suitable for eventual manufacture were then constructed. The ClaI-EcoRI fragment of pBG11 carrying the hCMV promoter and the chimeric A5B7 light chain gene was first cloned between the ClaI and EcoRI sites of pEE12 (22) to give plasmid pHMC20 (see Figure 5). Plasmid pHMC30 (see Figure 6) carrying the genes for both the chimeric light chain and chimeric IgG4 Fab' delta cys

- 27 -

heavy chain was constructed by ligating the large NaeI-FspI fragment of pHMC20 (carrying the light chain gene) to the EcoRV-FspI fragment of pHMC28, a derivative of pBG14 in which the gpt gene has been removed from the BamHI site. pHMC30 is a double gene plasmid suitable for development of an amplifiable cell line, using the mouse myeloma cell line NSO as host cell line, expressing chimeric A5B7 Fab' since it contains the GS cDNA for selection of transfectants. Selection and amplification of transfectants in CHO cells requires expression of the GS minigene rather than the cDNA. A double gene plasmid suitable for development of an amplifiable CHO cell line was constructed by ligating the MluI-FspI fragment of pHMC30, carrying both the chimeric light and heavy chain expression units, with the GS minigene containing fragment of pEE14 (25). The resulting plasmid, designated pHMC31 (see Figure 6), was transfected into CHO-K1 cells with selection on 25  $\mu$ M MSX. Specific production rates were determined on these transfectants, and seven chosen for amplification. The specific production rates for these seven transfectants before amplification were as follows (in units of  $\mu$ g/ $10^6$  cells/24hrs): HC3.36, 1.3; HC3.21, 0.65; HC3.33, 0.65; HC5.19, 0.14; HC5.24, 3.4; HC5.33, 3.7; HC5.39, 0.35. Selection for cells potentially with high copy number of the inserted plasmid sequences was achieved by increasing the MSX concentration to between 100 and 1000  $\mu$ M, screening for surviving cell lines and measuring specific production rates. Specific copy number estimates were not done.

#### C. Purification of Chimeric A5B7 IgG1

Chimeric IgG1 was purified by a modification of the procedure described for B72.3 by Colcher et al (26). CHO cell supernatants were concentrated by spiral cartridge ultrafiltration, then purified by affinity chromatography

- 28 -

on protein A Sepharose, with elution at pH3. Reducing and non-reducing SDS-PAGE showed the purified antibody to be fully assembled, with a purity of > 95%.

D. Purification and Cross-linking of Chimeric A5B7 Fab'

Chimeric A5B7 Fab' was purified by ion-exchange chromatography on DEAE-Sepharose following by hydrophobic interaction chromatography on octyl-Sepharose. CHO cell culture supernatant containing A5B7 Fab' was concentrated ten fold by ultrafiltration and diluted to the original volume with 10mM tris pH 7.5 to reduce the conductivity to < 4 mS. This material was then applied to a column of DEAE-Sepharose fast flow pre-equilibrated with 10mM tris pH 7.5, and the flow through which contains the Fab' collected. The flow through from the DEAE-Sepharose column was then concentrated by ultrafiltration and made 2M in ammonium sulphate. Any precipitate was removed by centrifugation and the sample then applied to a column of octyl-Sepharose pre-equilibrated with 10mM tris pH 7.5 containing 2M ammonium sulphate. The Fab' bound to the column and was washed with equilibration buffer and eluted by decreasing the ammonium sulphate concentration to 1M. The elute was then dialysed into 100mM sodium acetate/citrate pH6 and concentrated by ultrafiltration.

The purified Fab' was cross-linked by firstly generating a free thiol at the hinge followed by cross-linking with 1,6-bismaleimido-hexane. Partial reduction to generate a free thiol was achieved by incubation of the Fab' with 4.5mM  $\beta$ -mercaptoethylamine for 30 minutes at 37°C. The reducing agent was then removed by desalting on a column of Sephadex G-25 and the reduced Fab' immediately cross-linked by incubation with 1,6-bismaleimido-hexane at a molar ratio of 1:2.2 bismaleimido-hexane:Fab' with a Fab' concentration of 0.9 mg/ml. After overnight incubation

- 29 -

at 37°C the cross-linked material was purified by HPLC gel filtration using a DuPont Zorbax GF-250XL column in 0.2M phosphate pH 7.0. The cross-linking yield was approximately 58%.

The purified Fab' and cross-linked di-Fab (DFM) were analysed by SDS-PAGE under both reducing and non-reducing conditions (Figure 7). The purified Fab' ran as expected with a molecular weight of approximately 50 KDa under non-reducing conditions which reduced to Fd' and light chains at 25KDa. The purified cross-linked di-Fab revealed the expected molecular weight for the non-reduced dimer of 100 KDa which reduced to cross-linked Fd' at approximately 50 KDa and light chain at approximately 25 KDa.

E. Antigen Binding Activity of Chimeric A5B7 IgG1, Fab' and DFM

The relative potencies of murine and chimeric IgGs and fragments were measured by the competition RIA. The results are given in Table 1. All the bivalent species - including the chimeric DFM - gave potency equivalent to that of murine A5B7 IgG. The murine Fab' rendered monovalent by alkylation, showed a tenfold reduced potency, as would be predicted by avidity considerations. The monovalent chimeric Fab', however, displayed an intermediate potency. Measurements of binding activity on the same samples using the direct binding ELISA in competition mode gave very similar results, with the chimeric Fab' again showing an intermediate potency. Since the chimeric Fab' was not alkylated its increased binding activity compared to the murine Fab' is likely to be due to some degree of antigen induced dimerisation.

Table 1

Relative potencies of various A5B7 constructs by  
competition RIA

<u>Construct</u>	<u>% Relative Potency</u>
Chimeric IgG	100
Murine IgG	93 + 23
Chimeric DFM	104 + 28
Murine F(ab) <sub>2</sub>	97 + 22
Chimeric Fab'	20 + 15
Murine Fab'	8 + 5



Example 4

Humanised, CDR-grafted versions of A5B7 were also prepared.

Construction and Expression of CDR-grafted A5B7 Genes

Figure 1 shows the DNA and amino acid sequences of the V<sub>L</sub> and V<sub>H</sub> domains for A5B7. CDR-grafted V<sub>H</sub> and V<sub>L</sub> domains were designed substantially as described in International Patent Application No. PCT/GB 90/02017. The amino acid sequence of A5B7 V<sub>H</sub> shows considerable homology to the consensus sequence of the human V<sub>H</sub> III subgroup, as defined by Kabat *et al.*, (15), while the V<sub>L</sub> sequence shows considerable homology to those of the human VII and III subgroups. The human framework sequences available within these subgroups are: LAY(V<sub>H</sub>:V<sub>L</sub>), POM(V<sub>H</sub>:V<sub>L</sub>), KOL(V<sub>H</sub>):REI(V<sub>L</sub>), KOL(V<sub>H</sub>): EU(V<sub>L</sub>), TUR(V<sub>H</sub>): REI(V<sub>L</sub>), TUR(V<sub>H</sub>):EU(V<sub>L</sub>), TEI(V<sub>H</sub>):REI(V<sub>L</sub>), TEI(V<sub>H</sub>):EU(V<sub>L</sub>). Of these LAY was chosen as the human framework because it has the highest homology to A5B7 and also the potential advantage of matched V<sub>H</sub> and V<sub>L</sub> chains. CDR sequences and other residues potentially important for antigen binding were identified as described in International Patent Application No. PCT/GB 90/02017, and for each V region two constructs were assembled. The first constructs, gL1 and gH1, contain murine sequences in the CDRs and at other positions predicted to be important for antigen binding and at which human and A5B7 sequences differ. The gL1 light chain has murine CDRs at residues 24-34 (CDR1), 50-56 (CDR2) and 89-97 (CDR3) and additional murine residues within the frameworks at residues 1, 2, 3, 4, 46 and 71. The gH1 heavy chain has murine CDRs at residues 26-35 (CDR1), 50-65 (CDR2) and 95-102 (CDR3) and additional murine residues within the frameworks at residues 1, 48, 49, 72, 73, 76 and 93.

- 32 -

The second constructs, gL2 and gH2, are more conservative, containing the murine sequences present in the first constructs together with three extra murine residues for V<sub>L</sub> and two for V<sub>H</sub>. For gL2 these residues (positions 21, 47 and 73 on the Kabat numbering system) are potentially involved in packing of the domain. For gH2 the extra murine residues are at positions (82b and 86) where LAY has amino acids which are unusual for human V<sub>H</sub> sequences and where A5B7 has residues of more common occurrence in human V<sub>H</sub>s.

Figures 8, 9, 10 and 11 show the DNA and amino acid sequences of gL1, gL2, gH1 and gH2 respectively. In these Figures single letter underlining in the amino acid sequences indicate a residue in the framework region which has been changed to the corresponding murine residue. Also in these Figures solid single line underlining of the amino acid sequences indicates the CDR residues. These DNA sequences were assembled from oligonucleotides (indicated by double line underlining in the respective Figure) by the PCR overlap-assembly procedure, using a Polymerase Chain Reaction (PCR) procedure, using oligonucleotides of approximately 80 bases alternating on the sense and anti-sense strands. The oligonucleotides overlapped by 20 bases, such that annealing led to the formation of partially double stranded molecules. The gaps were filled in by Taq polymerase and the double stranded material amplified by PCR using short oligonucleotides corresponding to the sequence of the 5' end of each strand as amplifiers. The amplified fragments were digested with appropriate restriction enzymes to expose the restriction sites for cloning.

Amplified fragments of the appropriate size were digested with HindIII and ApaI for V<sub>H</sub>, and BstBI and SphI for V<sub>L</sub> to

- 33 -

expose the cloning sites. The  $V_H$  fragments were cloned into the expression vector pMRR014 and the  $V_L$  fragments into pMRR010. pMRR010 and pMRR014 are hCMV expression vectors designed to accept humanised V regions so as to be readily expressed transiently in CHO or COS cells and then readily to be reconstructed to give a single vector capable of stable expression and gene amplification in NSO cells. This gave plasmids pAL43 (for gL1), pAL44 (gL2), pAL45 (gH1) and pAL46 (gH2) as shown in Figure 12. These plasmids contain the full length CDR-grafted antibody genes (IgG1 for heavy chain, kappa for light chain) in a configuration suitable for expression in CHO cells. Clones containing the correct sequence were identified by DNA sequencing.

In order to assess the CEA binding activity of the grafted chains co-expression, experiments in a transient CHO cell system were first performed with chimeric partners. Thus pAL43 and pAL44 were co-transfected into the CHO L761 h cell line (27) together with the chimeric A5B7 heavy chain expression plasmid pBG7, while pAL45 and pAL46 were co-transfected with the light chain expression plasmid pBG11. Co-transfections of pBG7 and pHMC19 were also performed to provide a chimeric/chimeric standard against which to compare activity of the chimeric/grafted hybrids. Figure 13 shows the results of direct CEA binding ELISAs on the crude supernatants resulting from these transfections, and indicates that all the grafted/chimeric hybrids show binding activity similar to that of the chimeric/chimeric standard. Considerable variation was observed between the various hybrids in the yields of antibody. This variation was also very apparent when grafted/grafted co-transfections were performed. Indeed, the yields observed for gL1/gH1 and gL2/gH1 were too low to permit reliable estimates of CEA

- 34 -

binding activity. Both the gL1/gH2 and gL2/gH2 combinations, however, bound CEA at approximately 60% as well as the double chimeric antibody in the direct binding assay (see Figure 14). Competition RIAs were also performed on the crude CHO cell supernatants for gL1/gH2 and gL2/gH2. The results, shown in Table 2, show that these grafted variants displayed approximately 42% and 47% respectively of the potency of the chimeric in these more stringent assays, with gL2/gH2 showing slightly greater potency than gL1/gH2.

Table 2

Estimates of Anti-CEA Activity in Transfected CHO Cell  
Supernatants for Grafted Variants of A5B7 by Competition  
RIA

Undiluted

<u>Construct</u>	<u>Specific</u> <u>activity</u>	<u>relative</u> <u>potency</u>
Chimeric A5B7	1.17	100±6
Grafted A5B7 gL1/gH2	0.49	42±4
Grafted A5B7 gL2/gH2	0.55	47±3

Example 5

Similarly CDR-grafted A5B7 Fab' genes were constructed and expressed.

A. Construction of CDR-grafted A5B7 Fab' Genes

pMRR020 is a pEE6 gpt expression plasmid with restriction sites such that coding sequences of the human IgG4 CH1 and delta cys (i.e. single cysteine variant) hinge domains (see Figure 15). A fragment containing these two domains was isolated by performing a PCR reaction on pMRR020 using oligonucleotide R1053 as the forward primer and R2371 as the back primer as shown below.

R1053 5' GTCGACAGACTAACAGACTGTTCC 3'

R2371 5' ATGATCAATGAATTCATCATGGGGCTGATGGGCACGGGGGACCATATTT  
GGACTC 3'

Use of the latter primer results also in the removal of the inconvenient Apal site in the hinge coding region. The PCR reaction produced a fragment of 320bp, which was cloned into pAL45 and pAL46 to give pAL49 and pAL50 respectively (Figure 15) carrying the full length CDR-grafted Fd delta cys genes. The CH1 and hinge domains and the cloning junction regions were sequenced to confirm the absence of secondary mutations.

B. Development of CHO Cell Lines Expressing CDR-grafted A5B7 IgG1 Whole Antibody and CDR-grafted A5B7 IgG4 Fab' delta cys genes

To make stable cell lines expressing CDR-grafted IgG1 whole antibody and CDR-grafted Fab' the gL1 and gL2 genes were first isolated as ClaI-EcoRI fragments from pAL43 and pAL44 and cloned into the vector pMRR017, a derivative of

- 37 -

pEE14 with a useful poly-linker inserted at the BamHI site to give plasmids pHMC36 and pHMC37 respectively (see Figure 16). The gH1(IgG1), gH2(IgG1), gH1(Fd delta cys) and gH2(Fd delta cys) genes were isolated as HindIII-BamHI fragments from pAL45, 46, 49 and 50 respectively and cloned along with an EcoRI-HindIII fragment carrying the SV40 polyA and hCMV promoter between the EcoRI and BamHI sites of pHMC36 to give plasmids pHMC43 (gL1-gH1), pHMC44(gL1-gH2), pAL53 (gL1-gH1Fd delta cys) and pAL54 (gL1-gH2Fd delta cys). These GS double gene expression plasmids (see Figure 16) were transfected into CHO-K1 cells to give CDR-grafted IgG1 whole antibody and CDR-grafted Fab' producing cell lines substantially as described in previous Examples.

- 38 -

Example 6Production of A5B7 antibody fragments in E. coli

Chimeric and CDR-grafted A5B7 Fab' fragments (the gLlgH2 CDR-grafted variant was used) were also expressed in an E. coli secretion system, this being the preferred expression host for large scale production of antibody fragments.

For expression/secretion in E. coli the natural signal sequences of the A5B7 heavy and light chains were first replaced with the signal sequence of the E. coli outer membrane protein ompA (Movva et al, 28). A 92 base pair fragment encoding the ompA signal sequence and including the ompA translation initiation region was assembled from oligonucleotides and cloned into the phagemid vector pSK<sup>+</sup> (from Stratagene Cloning Systems) between the XhoI and HindIII sites. The DNA and amino acid sequence of the 92 base pair fragment were as follows:

metlysllysthralailealailealavalala  
TCGAGTTCTAGATAACGAGGCGTAAAAAATGAAAAGACAGCTATCGCGATTGCAGTGGCA  
CAAGATCTATTGCTCCGCATTTTTTACTTTTTCTGTCGATAGCGCTAACGTCACCGT  
  
leualaglyphealathrvalalaglnala  
CTGGCTGGTTTCGCTACCGTAGCGCA  
GACCGACCAAAGCGATGGCATCGCGTTCTGA

A clone shown by DNA sequencing to carry the above sequence in pSK<sup>+</sup> was designated pSKompA.

For the chimeric A5B7 light chain a 650 base pair SacI-EcoRI fragment encoding most of V<sub>L</sub> and all of C kappa was isolated from pHMC19. A precise fusion of the



- 39 -

chimeric Light chain to the ompA signal sequence was made by ligating this SacI-EcoRI fragment into pSKompA digested with HindIII and EcoRI together with a 54 base pair HindIII-SacI fragment assembled from oligonucleotides and comprising the DNA sequence encoding the 3' region of the ompA signal sequence and the 5' region of A5B7 V<sub>L</sub>. The sequence of the 51 base pair fragment was as follows:

```

5'  AGCTCAAAGTGTCTCTCCAGTCTCCAGCAATCCTGTCTGCATCTC      3'
3'      GTTTGACAAGAGAGGGTCAGAGGTCGTTAGGACAGACGTAGAGGTCC  5'

```

A clone containing the correct sequence was identified by DNA sequencing and designated pSKompA-cLc.

For the chimeric A5B7 heavy chain a 580 base pair AvalI-EcoRI fragment encoding most of V<sub>H</sub> and all of the CH1 and (delta cys) hinge domains was isolated from pBG14. A precise fusion of the chimeric heavy chain to the ompA signal sequence was made by ligating the AvalI-EcoRI fragment into pSKompA digested with HindIII and EcoRI together with a 120 base pair fragment assembled from oligonucleotides and comprising the DNA sequence encoding the 3' end of the ompA signal sequence and the 5' region of V<sub>H</sub>. The sequence of the 120 base pair fragment was as follows:

```

5'  AGCTGAGGTGAAGCTTGTGGAGTCTGGAGGAGGGTTGGTACAGCCTGGGGGTTCTCTGA
3'      CTCCACTTCGAACACCTCAGACCTCCTCCGAACCATGTCGGACCCCCAAGAGACT

GACTCTCCTGTGCAACTTCTGGGTTACCTTCACTGATTACTACATGAACTGG      3'
CTGAGAGGACACGTTGAAGACCCAAGTGGAAGTGACTAATGATGTACTTGACCCAGG  5'

```

A clone containing the correct sequence was identified by DNA sequencing and designated pSKompA-cFd.

- 40 -

For expression of the chimeric Fab' the ompA-cLc fusion was then removed from pSKompA-cLc on a XhoI-EcoRI fragment and cloned into the expression vector pACTac digested with SalI and partially with EcoRI (see Figure 17). pACTac was constructed by replacing the Amp<sup>r</sup> selectable marker and pUC18-derived replication functions of the expression plasmid, pTTQ9 (Amersham International) with the Cm<sup>r</sup> selectable marker and replication functions of pACYC184 (Chang & Cohen, 1978, J. Bacteriol. 134: 1141-1156). (Partial EcoRI digestion was required because pACTac contains a second EcoRI site, in the Cm<sup>r</sup> gene.) A plasmid with ompA-cLc inserted adjacent to the tac promoter was identified by restriction mapping and DNA sequencing and designated pMRR024.

The ompA-cFd fragment was removed from pSKompA-cFd as a XhoI-SmaI fragment and cloned into pSP73 (Promega Corporation) digested with SalI and PvuII, to give a plasmid designated pMRR027. The ompA-cFd fusion was then removed from pMRR027 as an EcoRI fragment, which was cloned into pMRR024 partially digested with EcoRI. A clone carrying ompA-cFd oriented for transcription from the tac promoter (along with ompA-cLc) was identified by restriction mapping and DNA sequencing and designated pMRR028.

pMRR028 was transformed into E. coli strain W3110 (ATCC strain 27325). Strain W3110 (pMRR028) was grown in a 1.5L fermenter in medium containing chloramphenicol to maintain selection for retention of the plasmid. At a culture O.D 600nm of 10 expression of the A5B7 Fab' genes from the tac promoter was induced by adding the inducer IPTG to a final concentration of 1mM. Direct CEA binding assays were performed on crude culture supernatant samples taken from this culture at time points 0, 3, 4, 5, 6, 7

- 41 -

and 8 hours after induction. The results of these assays, together with that of a chimeric A5B7 Fab' standard made and purified from mammalian cells are shown in Figure 18. They demonstrate the accumulation of active chimeric A5B7 Fab' in the E. coli culture medium. SDS-PAGE analysis on the same crude culture medium samples revealed proteins with mobility of the size expected for Fab' heavy and light chains. N-terminal protein sequencing on these proteins revealed the N-terminal amino acid sequences of mature A5B7 heavy and light chains, showing that the ompA signal sequence had been accurately cleaved from both. Estimates (by OD 280nm measurements and by SDS-PAGE) for the chimeric Fab' in the E. coli culture medium were performed: the results suggested yields in excess of 30mg/L after purification.

For the CDR-grafted A5B7 Fab' light chain a 620 base pair HphI-EcoRI fragment encoding most of V<sub>L</sub> for the gL1 variant and all of C kappa was isolated from pAL43. A precise fusion of the grafted light chain to the ompA signal sequence was made by ligating the Hph-EcoRI fragment into pSKompA digested with HindIII and EcoRI together with a 62 base pair fragment assembled from oligonucleotides and encoding the 3' end of the ompA signal sequence and the 5' end of the CDR-grafted V<sub>L</sub>. The sequence of the synthetic fragment was as follows:

AGCTCAGACTGTACTCACTCAGAGTCCAAGTAGTCTCAGTGTAAGTGTAGGTGATAGGGTAA  
GTCTGACATGAGTGAGTCTCAGGTTTCATCAGAGTCACATTCACATCCACTATCCCAT

A clone carrying the correct sequence was identified by DNA sequencing and designated pMRR034.

For the CDR-grafted A5B7 Fab' heavy chain gene a 720 base pair PvuII-EcoRI fragment encoding most of V<sub>H</sub> for the gH2

- 42 -

variant and all of CH1 and the (delta cys) hinge domains was isolated from pAL50. A precise fusion of this grafted H chain to the ompA signal sequence was made by ligating this PvuII-EcoRI fragment into pSKompA digested with HindIII and EcoRI together with a very short fragment assembled from oligonucleotides and encoding the 3' end of the ompA signal and the 5' end of the CDR-grafted V<sub>H</sub>. The sequence of the short adaptor fragment was as follows:

5' AGCTGAGGTGCAG 3'  
3' CTCCACGTC 5'

A clone containing the correct sequence was identified by DNA sequencing and designated pMRR037.

For expression of CDR-grafted Fab' the ompA-gL1 fusion was taken from pMRR034 as a XhoI-EcoRI fragment and cloned into pACTac digested with SalI and partially with EcoRI. A clone carrying ompA-gL1 adjacent to the tac promoter was identified by restriction mapping and DNA sequencing and designated pMRR038. The ompA-gH2 fusion was then taken from pMRR037 as a XhoI-SmaI fragment and cloned into pSP73 doubly digested with PvuII and EcoRI to give a plasmid designated pMRR041. The ompA-gH2 fusion was then removed from pMRR041 as an EcoRI fragment and cloned into pMRR038 partially digested with EcoRI. A clone carrying the ompA-gH2 fusion oriented for transcription from the tac promoter (along with ompA-gL1) was identified by restriction mapping and DNA sequencing and designated pMRR045.

pMRR045 was transformed into E. coli strain W3110 and the W3110 (pMRR045) strain resulting was grown in a 1.5L fermenter. Expression of the CDR-grafted Fab' genes was induced as described above for the chimeric Fab' genes.

- 43 -

Crude culture supernatant samples from this culture at time points 1, 4, 5, 6, 11 and 22 hours after induction were used in direct CEA binding assays and yield estimates. The results of the CEA binding assays are given in Figure 19 and show the accumulation of material active in antigen binding. SDS-PAGE analysis of these supernatant samples demonstrated the presence of proteins of the size expected, and suggested yields in excess of 30mg/L.

References

1. Kohler & Milstain, *Nature*, 265, 495-497, 1975.
2. Begent et al, *Br. J. Cancer*, 62: 487 (1990).
3. Verhoeyen et al, *Science*, 239, 1534-1536, 1988.
4. Riechmann et al, *Nature*, 332, 323-324, 1988.
5. Queen et al, *Proc. Natl. Acad. Sci., USA*, 86: 10029-10033, 1989 and WO 90/07861.
6. Ehrlich, P., *Collected Studies on Immunity*, 2, John Wiley & Sons, New York, 1906.
7. Levy & Miller, *Annu. Rev. Med.*, 34, 107-116, 1983.
8. Schlom & Weeks, *Important Advances in Oncology*, 170-192, Wippincott, Philadelphia, 1985.
9. Sahagan et al, *J. Immunol.*, 137, 3 1066-1074.
10. Nishimura et al, *Cancer Res.*, 47 999-1005, 1987.
11. Harwood et al, *Br. J. Cancer*, 54, 75-82, 1986.
12. Maniatis et al, *Molecular Cloning*, Cold Spring Harbor, New York, 1982.
13. Primrose and Old, *Principles of Gene Manipulation*, Blackwell, Oxford, 1980.
14. Jones et al, *Nature*, 54, 75-82, 1986.
15. Kabat et al, (1987), *Sequences of Proteins of Immunological Interest*, US Department of Health and Human Services, NIH, USA, and Wu, T.T., and Kabat, E.A., *J. Exp. Med.*, 132, 211-250, 1970.
16. Gubler and Hoffman, *Gene*, 25, 263-269, 1983.
17. Melton et al, *Nucl. Acids Res.*, 12, 7035-7056, 1984.
18. Honjo et al, *Cell*, 18, 559-568, 1979.
19. Max et al, *J. Biol. Chem.*, 256, 5116-5120, 1981.
20. Sanger et al, *PNAS*, 74, 5463-5467, 1977.
21. Stephens and Cockett, *Nucl. Acids Res.*, 17, 7110, 1989

- 45 -

22. Krawinkel and Rabbits, EMBO J., 1, 403-407, 1982.
23. Kramer et al, Nucl. Acids Res., 12, 9441-9446, 1984.
24. Whittle et al, Prot. Eng., 1, 6, 499-505, 1987.
25. Bebbington, C.R., "Expression of Antibody Genes in Non-Lymphoid Mammalian Cells", Methods in ... (in Press).
26. Colcher et al, (1989), Cancer Res., 49, 1738-1745.
27. Cockett et al, Nucl. Acids. Res., 19, 319-325.
28. Movva et al, J. Bio. Chem., 255, 27-29, 1980.

CLAIMS

1. A humanised antibody molecule (HAM) having specificity for carcinoembryonic antigen and having an antigen binding site wherein at least one of the complementarity determining regions (CDRs) of the variable domains is derived from the mouse monoclonal antibody A5B7 (A5B7 MAb) and the remaining immunoglobulin-derived parts of the HAM are derived from a human immunoglobulin.
2. A HAM according to Claim 1 which is a chimeric humanised antibody.
3. A HAM according to Claim 1 which is a CDR-grafted humanised antibody.
4. A HAM according to any one of Claims 1-3 when produced by recombinant DNA technology.
5. A HAM according to any one of claims 1-4, which comprises a complete antibody molecule, or a Fab, Fab', (Fab')<sub>2</sub> or Fv fragment, or a single chain antibody fragment.
6. A HAM according to any one of claims 1-5, wherein an effector or reporter molecule is attached thereto.
7. A CDR-grafted HAM according to any one of Claims 3-6 comprising LAY, POM, TUR, TEI, KOL, NEWM, REI or EU variable region framework sequences for the heavy and/or light chains.
8. A CDR-grafted HAM according to Claim 7 comprising LAY variable region framework sequences for both the heavy and light chains.



- 47 -

9. A CDR-grafted HAM according to any one of Claims 3-8 having A5B7 CDRs at positions 24 to 34 (CDR1), 50 to 56 (CDR2) and 92 to 96 or 89 to 97 (CDR3) of the light chain variable region.
10. A CDR-grafted HAM according to any one of Claims 3-9 comprising A5B7 residues at one or more of positions 1, 2 and/or 3, 46, 47, 49, 60, 70, 84, 85 and 87, preferably at at least positions 46 and 47, of the light chain variable region.
11. A CDR-grafted HAM according to any one of Claims 3-10 having A5B7 CDRs at positions 24 to 35 or 26 to 35 (CDR1), 50 to 65 (CDR2) and 95 to 100 or 94 to 100 (CDR3) of the heavy chain variable region.
12. A CDR-grafted HAM according to any one of Claims 3-11 having A5B7 residues at any one or more of positions 23 and/or 24, 71 and/or 73, 48 and/or 49, 69, 76 and/or 78, 80, 88 and/or 91 and 6 of the heavy chain variable region.
13. A CDR-grafted HAM according to Claim 8, comprising A5B7 residues at positions 1, 2, 3, 4, 46 and 71, and especially also at positions 21, 47 and 73, of the light chain, and at positions 1, 24, 48, 49, 72, 73, 76 and 93, and especially also at positions 82b and 86, of the heavy chain.
14. A CDR-grafted HAM according to Claim 13, comprising A5B7 CDRs at positions 24 to 34 (CDR1), 50 to 56 (CDR2) and 89 to 97 (CDR3) of the light chain, and at positions 26 to 35 (CDR1) 50 to 65 (CDR2) and 95 to 102 (CDR3) of the heavy chain.

- 48. -

15. A therapeutic or diagnostic composition comprising a HAM according to any one of the preceding claims in combination with a pharmaceutically acceptable excipient, diluent or carrier.
16. A therapeutic or diagnostic method comprising administering an effective amount of a therapeutic or diagnostic composition according to Claim 15 to a human subject.
17. A process for producing a HAM according to any one of claims 1 to 14, which process comprises:-
  - (a) producing in an expression vector an operon having a DNA sequence which encodes an antibody heavy or light chain comprising a variable domain wherein at least one of the CDRs of the variable domain is derived from the A5B7 MAb and the remaining immunoglobulin-derived parts of the antibody chain are derived from a human immunoglobulin;
  - (b) producing in an expression vector an operon having a DNA sequence which encodes a complementary antibody light or heavy chain comprising a variable domain wherein at least one of the CDRs of the variable domain is derived from the A5B7 MAb and the remaining immunoglobulin-derived parts of the antibody chain are derived from a human immunoglobulin.
  - (c) transfecting a host cell with the or each vector; and
  - (d) culturing the transfected cell line to produce the HAM.

- 49 -

18. A process according to Claim 17, wherein the heavy and light chain encoding sequences are present on the same vector.
  19. A process according to Claim 17, wherein the heavy and light chain encoding sequences are present on separate vectors.
  20. A process according to any one Claims 17-19 for the production of an antibody fragment in which the host cell is a bacterial host cell.
  21. A process according to any one of Claims 17-19 in which the host cell is a mammalian host cell.
-

1/17

Fig. 1

A5B7: light chain sequence*DNA and protein sequence of the VI domain*

ATGGATTTTCAAGTGCAGATTTTCAGCTTCCTGCTAATCAGTGCTTCAGTCATAATGTCC  
M D F Q V Q I F S F L L I S A S V I M S  
↓  
AGAGGACAACTGTTCTCTCCAGTCTCCAGCAATCCTGTCTGCATCTCCAGGGGAGAAG  
R G Q T V L S Q S P A I L S A S P G E K  
GTCACATGACTTGCAGGGCCAGCTCAAGTGTAACTTACATTCACTGGTACCAGCAGAAG  
V T M T C R A S S S V T Y I H W Y Q Q K  
CCAGGATCCTCCCCCAATCCTGGATTTATGCCACATCCAACCTGGCTTCTGGAGTCCCT  
P G S S P K S W I Y A T S N L A S G V P  
GCTCGCTTCAGTGGCAGTGGGTCTGGGACCTCTTACTCTCTCACAATCAGCAGAGTGGAG  
A R F S G S G S G T S Y S L T I S R V E  
GCTGAAGATGCTGCCACTTATTACTGCCAACATTGGAGTAGTAAACCACCGACGTTCCG  
A E D A A T Y Y C Q H W S S K P P T F G  
GGAGGCACCAAGCTGGAAATCAAACGG  
G G T K L E I K R


A5B7: heavy chain sequence*DNA and protein sequence of the Vh domain*

ATGAAGTTGFGCTGAACTGGATTTTCCTTGTAACACTTTTAAATGGTATCCAGTGTGAG  
M K L W L N W I F L V T L L N G I Q C E  
↓  
GTGAAGCTGGTGGAGTCTGGAGGAGGCTTGGTACAGCCTGGGGGTCTCTGAGACTCTCC  
V K L V E S G G G L V Q P G G S L R L S  
TGTGCAACTTCTGGGTTACCTTCACTGATTACTACATGAACTGGGTCCGCCAGCCTCCA  
C A T S G F T F T D Y Y M N W V R Q P P  
GGAAAGGCACTTGAGTGGTTGGGTTTTATTGGAAACAAAGCTAATGGTTACACAACAGAG  
G K A L E W L G F I G N K A N G Y T T E  
TACAGTGCATCTGTGAAGGGTCGGTTCACCATCTCCAGAGATAAATCCCAAAGCATCCTC  
Y S A S V K G R F T I S R D K S Q S I L  
TATCTTCAAATGAACACCCTGAGAGCTGAGGACAGTGCCACTTATTACTGTACAAGAGAT  
Y L Q M N T L R A E D S A T Y Y C T R D  
AGGGGGCTACGGTTCTACTTTGACTACTGGGGCCAAGGCACCACTCTCACAGTCTCCTCA  
R G L R F Y F D Y W G Q G T T L T V S S

2/17

## Construction of A5B7 chimeric heavy chain gene.

Fig. 2



E = EcoRI  
 B = BamHI  
 H = HindIII  
 Ba = BstI

SUBSTITUTE SHEET

3/17



Construction of A5B7 chimeric light chain gene.

Fig. 3

E = EcoRI  
H = HindIII  
N = NarI

4/17

Fig. 4



cHC = chimeric heavy chain.

cLC = chimeric light chain.

mHC = mouse heavy chain.

mLC = mouse light chain.

SUBSTITUTE SHEET

5/17




Fig. 5


VECTORS FOR cA5B7 EXPRESSION

SUBSTITUTE SHEET




6/17


Fig. 6



GS vector for cL-clgG1  
expression in NS0 cells



GS vector for cL-clgG4Fd'  
expression in NS0 cells




GS vector for cL-clgG4Fd'  
expression in CHO cells

GS VECTORS FOR cA5B7 IgG1 AND cA5B7 Fab'

7/17

## Purification and cross-linking of A5B7 cFab'



1. Molecular weight markers, non-reduced
2. A5B7 cDFM, non-reduced
3. A5B7 cFab', non-reduced
4. A5B7 cFab', reduced
5. A5B7 cDFM, reduced

10-20% acrylamide gradient gel, Coomassie blue stained

Fig. 7

SUBSTITUTE SHEET

## A5B7 LIGHT CHAIN GRAFT L.

OLIGO L1 (21)

M S V P T Q V L G L L L W L T D A R C Q T Y L T Q S  
 GGACTGTTCCGAAGCCGCCACCATGCTGTCTGCCACCCAGTCTCTGGCTTACAGATGCCAGATGTGACACTCAGA  
 CCTGACAAAGCTTCGGCGGTGGTACAGACAGGGGTGGTTCAGGAGCTGAGGACGACGACCCGAATGCTACGGTCTACAGTCTGNCATGAGTGAGTCT

BstBI

OLIGO L5 (81)

P S S L S V S V G D R V T I T C R A S S S V T Y I H W Y Q Q K P G  
 GTCCAAAGTAGTCTCAGTGTAGTGTAGGTGATAGGGTAACATATCACTTGTAGGGCCAGTAGTAGTGTAACTTATATCCATTGTTATCAGCAGAAACCCAGG  
 CAGGTTTCATCAGAGTCACATTCCATCCACTATCCCATTTGATAGTGAACATCCCGGTCTCATCAGATTGANTATAGGTAAACCATAGTCGGTCTTTGGTCC

OLIGO L6 (87)

OLIGO L3 (87)

L A P K S L I Y A T S N L A S G V P S R F S G S G T D Y T F T  
 TCTGCCCAAAAGTCTCATCTATGCCACTAGTAACTCGCCAGTGGGTGATACCTATGATTCAGTGTAGCGGTAGTGGTACTGATTACTTTCACT  
 AGAGCGGGGTTTTTCAGAGTAGATACGGTGTATCATTTGGAGCGGTCCACACATGGTAGATCTAAGTCACCATCGGCATCACCATGACTAATATGAAGTGA

XbaI

OLIGO L7 (90)

OLIGO L4 (90)

I S S L Q P E D I A T Y Y C O H W S S K P P T F G Q G T K V E V K R  
 ATCAGTAGTCTCCAGCCAGAAGATATGCCACTTACTATTGCCAGCATTTGGAGTAGTAAACCCACCACTTCGGTTCAGGGTACTAAGCTAGAGTAAAC  
 TAGTCATCAGAGGTGGTCTTCTATAGCGGTGAATGATAACGGTCGTAACTCATCTTTGGTGGTTGAAGCCAGTCCCATGATTTCACTTTTGG

T

GTACGGGCGCG

CATGCCGCGC

OLIGO L8 (21)

SplI

8/17

Ti. 0

DNA AND PROTEIN SEQUENCE FOR  
gL1-A5B7 VARIABLE REGION

SUBSTITUTE SHEET



OLIGO I -1 H8 ApaI

# SUBSTITUTE SHEET




Fig. 11

DNA AND PROTEIN SEQUENCE FOR  
gH2-A5B7 VARIABLE REGION

SUBSTITUTE SHEET

12/17




Fig. 12

VECTORS FOR gA5B7  
EXPRESSION

SUBSTITUTE SHEET

13/17

## CEA binding A5B7 chimeric/grafted hybrid




Fig. 13

## CEA Binding A5B7 gHgL




Fig. 14



14/17




Fig. 15

VECTORS FOR gA5B7 Fab'  
EXPRESSION

SUBSTITUTE SHEET

NOT TO SCALE

15/17




Fig. 16

VECTORS FOR gA5B7 CHO CELL  
EXPRESSION

SUBSTITUTE SHEET

16/17




Fig. 17

Maps of A5B7 Fab' E.coli expression plasmids

SUBSTITUTE SHEET

17/17


CEA binding assay on E.coli supernatants  
containing A5B7 chimeric Fab'

Fig. 18


CEA binding assay on E.coli supernatants  
containing A5B7 grafted Fab'

Fig. 19

# INTERNATIONAL SEARCH REPORT

International Application No PCT/GB 91/01108

<b>I. CLASSIFICATION OF SUBJECT MATTER</b> (If several classification symbols apply, indicate all) <sup>6</sup> According to International Patent Classification (IPC) or to both National Classification and IPC IPC5: C 12 P 21/08, A 61 K 39/395, C 12 N 15/13, C 12 K 15/28														
<b>II. FIELDS SEARCHED</b> <div style="text-align: center; border: 1px solid black; padding: 2px;">Minimum Documentation Searched<sup>7</sup></div> <table style="width: 100%; border-collapse: collapse;"> <tr> <th style="width: 20%; border: 1px solid black;">Classification System</th> <th style="border: 1px solid black;">Classification Symbols</th> </tr> <tr> <td style="border: 1px solid black; padding: 5px;">IPC5</td> <td style="border: 1px solid black; padding: 5px;">A 61 K; C 12 P; C 12 N</td> </tr> </table> <div style="text-align: center; border: 1px solid black; padding: 2px;">Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in Fields Searched<sup>8</sup></div>			Classification System	Classification Symbols	IPC5	A 61 K; C 12 P; C 12 N								
Classification System	Classification Symbols													
IPC5	A 61 K; C 12 P; C 12 N													
<b>III. DOCUMENTS CONSIDERED TO BE RELEVANT<sup>9</sup></b> <table border="1" style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th style="width: 10%; border: 1px solid black;">Category<sup>*</sup></th> <th style="border: 1px solid black;">Citation of Document<sup>11</sup> with indication, where appropriate, of the relevant passages<sup>12</sup></th> <th style="width: 10%; border: 1px solid black;">Relevant to Claim No.<sup>13</sup></th> </tr> </thead> <tbody> <tr> <td style="border: 1px solid black; text-align: center; vertical-align: top;">Y</td> <td style="border: 1px solid black; padding: 5px;">WO, A1, 8910140 (CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED) 2 November 1989, see page 7, lines 3-13 and 21-24 and examples</td> <td style="border: 1px solid black; text-align: center; vertical-align: top;">1-6, 15-21</td> </tr> <tr> <td style="border: 1px solid black; text-align: center; vertical-align: top;">A</td> <td style="border: 1px solid black; padding: 5px;">Chemical Abstracts, volume 110, no. 15, 10 April 1989, (Columbus, Ohio, US), Barnett P et al.: "Tumor localization using monoclonal antibodies. II. Biodistribution of A5B7/indium-111 chelates", see page 363, abstract 131464s, &amp; Int. J. Cancer (Suppl. 3) 1988, ( ), 34- 37</td> <td style="border: 1px solid black; text-align: center; vertical-align: top;">1-21</td> </tr> <tr> <td style="border: 1px solid black; text-align: center; vertical-align: top;">A</td> <td style="border: 1px solid black; padding: 5px;">Br. J. Cancer, vol. 54, 1986, P.J. Harwood et al.: "Mapping epitope characteristics on carcinoembryonic antigen ", see page 75 - page 82</td> <td style="border: 1px solid black; text-align: center; vertical-align: top;">1-21</td> </tr> </tbody> </table>			Category <sup>*</sup>	Citation of Document <sup>11</sup> with indication, where appropriate, of the relevant passages <sup>12</sup>	Relevant to Claim No. <sup>13</sup>	Y	WO, A1, 8910140 (CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED) 2 November 1989, see page 7, lines 3-13 and 21-24 and examples	1-6, 15-21	A	Chemical Abstracts, volume 110, no. 15, 10 April 1989, (Columbus, Ohio, US), Barnett P et al.: "Tumor localization using monoclonal antibodies. II. Biodistribution of A5B7/indium-111 chelates", see page 363, abstract 131464s, & Int. J. Cancer (Suppl. 3) 1988, ( ), 34- 37	1-21	A	Br. J. Cancer, vol. 54, 1986, P.J. Harwood et al.: "Mapping epitope characteristics on carcinoembryonic antigen ", see page 75 - page 82	1-21
Category <sup>*</sup>	Citation of Document <sup>11</sup> with indication, where appropriate, of the relevant passages <sup>12</sup>	Relevant to Claim No. <sup>13</sup>												
Y	WO, A1, 8910140 (CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED) 2 November 1989, see page 7, lines 3-13 and 21-24 and examples	1-6, 15-21												
A	Chemical Abstracts, volume 110, no. 15, 10 April 1989, (Columbus, Ohio, US), Barnett P et al.: "Tumor localization using monoclonal antibodies. II. Biodistribution of A5B7/indium-111 chelates", see page 363, abstract 131464s, & Int. J. Cancer (Suppl. 3) 1988, ( ), 34- 37	1-21												
A	Br. J. Cancer, vol. 54, 1986, P.J. Harwood et al.: "Mapping epitope characteristics on carcinoembryonic antigen ", see page 75 - page 82	1-21												
<div style="display: flex; justify-content: space-between;"> <div style="width: 45%;"> <p><sup>10</sup> Special categories of cited documents:</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> </div> <div style="width: 45%;"> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance, the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance, the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art</p> <p>"A" document member of the same patent family</p> </div> </div>														
<b>IV. CERTIFICATION</b> <table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 50%; border: 1px solid black; padding: 5px;">           Date of the Actual Completion of the International Search            11th October 1991         </td> <td style="width: 50%; border: 1px solid black; padding: 5px;">           Date of Mailing of this International Search Report            25. 10. 91         </td> </tr> <tr> <td style="border: 1px solid black; padding: 5px;">           International Searching Authority            EUROPEAN PATENT OFFICE         </td> <td style="border: 1px solid black; padding: 5px;">           Signature of Authorized Officer  </td> </tr> </table>			Date of the Actual Completion of the International Search 11th October 1991	Date of Mailing of this International Search Report 25. 10. 91	International Searching Authority EUROPEAN PATENT OFFICE	Signature of Authorized Officer 								
Date of the Actual Completion of the International Search 11th October 1991	Date of Mailing of this International Search Report 25. 10. 91													
International Searching Authority EUROPEAN PATENT OFFICE	Signature of Authorized Officer 													

III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)		
Category	Citation of Document, with indication, where appropriate, of the relevant passages	Relevant to Claim No
Y	WO, A2, 8901783 (CELLTECH LIMITED) 9 March 1989, see the whole document	1-6,15-21
	--	
Y	Nature, vol. 332, March 1988, L Riechmann et al.: "Reshaping human antibodies for therapy", see page 323 - page 327	1-6,15-21
	--	
Y	EP, A1, 0323806 (CIBA-GEIGY AG) 12 July 1989, see page 5	1-6,15-21
	--	
A	Nature, vol. 342, November 1989, J.D. Rodwell: "Engineering monoclonal antibodies", see page 99 - page 100	1-21
	--	
A	Proc. Natl. Acad. Sci., vol. 86, December 1989, C Queen et al.: "A humanized antibody that binds to the interleukin 2 receptor", see page 10029-10033	1-21
	--	
A	Science, vol. 239, 1988, M Verhoeyen et al.: "Reshaping Human Antibodies: Grafting an Antilysozyme Activity", see page 1534 - page 1536	1-21
	--	
	-----	

**ANNEX TO THE INTERNATIONAL SEARCH REPORT  
ON INTERNATIONAL PATENT APPLICATION NO. PCT/GB 91/01108**

SA 49262

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report.  
The members are as contained in the European Patent Office EDP file on 30/08/91  
The European Patent office is in no way liable for these particulars which are merely given for the purpose of information.

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO-A1- 8910140	02/11/89	EP-A- 0414741	06/03/91
WO-A2- 8901783	09/03/89	AU-D- 2301388	31/03/89
		AU-D- 2301688	31/03/89
		AU-D- 2421888	31/03/89
		EP-A- 0329755	30/08/89
		EP-A- 0347433	27/12/89
		EP-A- 0348442	03/01/90
		JP-T- 2501190	26/04/90
		JP-T- 2501191	26/04/90
		JP-T- 2501800	21/06/90
		WO-A- 89/01782	09/03/89
		WO-A- 89/01974	09/03/89
EP-A1- 0323806	12/07/89	AU-D- 2759588	06/07/89
		JP-A- 2154696	14/06/90

For more details about this annex: see Official Journal of the European patent office, No. 12/82